Suppr超能文献

丙型肝炎病毒包膜糖蛋白E1抗原位点314 - 324与抗体IGH526复合物的结构

Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.

作者信息

Kong Leopold, Kadam Rameshwar U, Giang Erick, Ruwona Tinashe B, Nieusma Travis, Culhane Jeffrey C, Stanfield Robyn L, Dawson Philip E, Wilson Ian A, Law Mansun

机构信息

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.

出版信息

J Mol Biol. 2015 Aug 14;427(16):2617-28. doi: 10.1016/j.jmb.2015.06.012. Epub 2015 Jun 30.

Abstract

Hepatitis C virus (HCV) is a positive-strand RNA virus within the Flaviviridae family. The viral "spike" of HCV is formed by two envelope glycoproteins, E1 and E2, which together mediate viral entry by engaging host receptors and undergoing conformational changes to facilitate membrane fusion. While E2 can be readily produced in the absence of E1, E1 cannot be expressed without E2 and few reagents, including monoclonal antibodies (mAbs), are available for study of this essential HCV glycoprotein. A human mAb to E1, IGH526, was previously reported to cross-neutralize different HCV isolates, and therefore, we sought to further characterize the IGH526 neutralizing epitope to obtain information for vaccine design. We found that mAb IGH526 bound to a discontinuous epitope, but with a major component corresponding to E1 residues 314-324. The crystal structure of IGH526 Fab with this E1 glycopeptide at 1.75Å resolution revealed that the antibody binds to one face of an α-helical peptide. Single mutations on the helix substantially lowered IGH526 binding but did not affect neutralization, indicating either that multiple mutations are required or that additional regions are recognized by the antibody in the context of the membrane-associated envelope oligomer. Molecular dynamics simulations indicate that the free peptide is flexible in solution, suggesting that it requires stabilization for use as a candidate vaccine immunogen.

摘要

丙型肝炎病毒(HCV)是黄病毒科中的一种正链RNA病毒。HCV的病毒“刺突”由两种包膜糖蛋白E1和E2形成,它们共同通过与宿主受体结合并经历构象变化以促进膜融合来介导病毒进入。虽然在没有E1的情况下E2可以很容易地产生,但没有E2时E1无法表达,并且包括单克隆抗体(mAb)在内的用于研究这种重要的HCV糖蛋白的试剂很少。先前报道了一种针对E1的人源单克隆抗体IGH526可交叉中和不同的HCV分离株,因此,我们试图进一步表征IGH526的中和表位,以获取疫苗设计的信息。我们发现单克隆抗体IGH526与一个不连续表位结合,但主要成分对应于E1的314 - 324位残基。IGH526 Fab与该E1糖肽的晶体结构在1.75Å分辨率下显示,该抗体与α - 螺旋肽的一个面结合。螺旋上的单个突变显著降低了IGH526的结合,但不影响中和作用,这表明要么需要多个突变,要么在膜相关包膜寡聚体的背景下抗体识别其他区域。分子动力学模拟表明,游离肽在溶液中是灵活的,这表明它需要稳定化才能用作候选疫苗免疫原。

相似文献

1
Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.
J Mol Biol. 2015 Aug 14;427(16):2617-28. doi: 10.1016/j.jmb.2015.06.012. Epub 2015 Jun 30.
4
Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
J Virol. 2019 Jun 28;93(14). doi: 10.1128/JVI.02070-18. Print 2019 Jul 15.

引用本文的文献

3
Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.
Biol Proced Online. 2025 Jun 3;27(1):20. doi: 10.1186/s12575-025-00269-2.
5
Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and evade antibody recognition.
J Virol. 2024 Jan 23;98(1):e0084923. doi: 10.1128/jvi.00849-23. Epub 2024 Jan 4.
6
HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies.
Virus Evol. 2023 Nov 18;9(2):vead068. doi: 10.1093/ve/vead068. eCollection 2023.
7
Prospects for developing an Hepatitis C virus E1E2-based nanoparticle vaccine.
Rev Med Virol. 2023 Sep;33(5):e2474. doi: 10.1002/rmv.2474. Epub 2023 Aug 11.
8
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies.
Nat Commun. 2023 Jul 5;14(1):3980. doi: 10.1038/s41467-023-39659-z.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.
Curr Opin Virol. 2015 Apr;11:148-57. doi: 10.1016/j.coviro.2015.04.001. Epub 2015 Apr 29.
5
Antiviral treatment of hepatitis C.
BMJ. 2014 Jul 7;348:g3308. doi: 10.1136/bmj.g3308.
8
New hepatitis C therapies: the toolbox, strategies, and challenges.
Gastroenterology. 2014 May;146(5):1176-92. doi: 10.1053/j.gastro.2014.03.003. Epub 2014 Mar 12.
9
Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China.
PLoS One. 2013 Dec 17;8(12):e82598. doi: 10.1371/journal.pone.0082598. eCollection 2013.
10
The ins and outs of hepatitis C virus entry and assembly.
Nat Rev Microbiol. 2013 Oct;11(10):688-700. doi: 10.1038/nrmicro3098. Epub 2013 Sep 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验